AF
NMTR

Amalgamated Financial’s 9 Meters Biopharma NMTR Stock Holding History

Amalgamated Financial’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$22K Buy
+1,843
New +$25.2K ﹤0.01% 2724

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amalgamated Financial's NMTR Position: Q1 2022 in Review

Amalgamated Financial opened a new position in 9 Meters Biopharma (NMTR) in Q1 2022: 1,843 shares worth $22K. The stake represents ﹤0.01% of the portfolio and ranks #2724 among its holdings.

101 funds tracked by Wall St. Rank hold NMTR as of Q1 2022.

  • Amalgamated Financial held 1,843 shares of 9 Meters Biopharma worth $22K as of Q1 2022.
  • 9 Meters Biopharma was a new Amalgamated Financial position in Q1 2022.
  • 9 Meters Biopharma made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2724 holding.
  • 101 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.